{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:08:12Z","timestamp":1793513292102,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cgh.2023.11.018","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:06:45Z","timestamp":1701328005000},"page":"1067-1076.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-0118","authenticated-orcid":false,"given":"Alessandro","family":"Armuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond K.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Lichtenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parakkal","family":"Deepak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Regueiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Akukwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harris A.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Kozinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiuanlin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnnKatrin","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.11.018_bib1","series-title":"Zeposia [package insert]","year":"2023"},{"key":"10.1016\/j.cgh.2023.11.018_bib2","series-title":"Zeposia [summary of product characteristics]","year":"2023"},{"key":"10.1016\/j.cgh.2023.11.018_bib3","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/10600280211041907","article-title":"Ozanimod: a first-in-class sphingosine 1-phosphate receptor modulator for the treatment of ulcerative colitis","volume":"56","author":"Choi","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cgh.2023.11.018_bib4","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cgh.2023.11.018_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpdd.383","article-title":"Cardiac safety of ozanimod, a novel sphingosine-1-phosphate receptor modulator: results of a thorough QT\/QTc study","volume":"7","author":"Tran","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.cgh.2023.11.018_bib6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3390\/cells11132058","article-title":"Sphingosine-1-phosphate (S1P) and S1P signaling pathway modulators, from current insights to future perspectives","volume":"11","author":"Bravo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cgh.2023.11.018_bib7","series-title":"Gilenya [package insert]","year":"2023"},{"key":"10.1016\/j.cgh.2023.11.018_bib8","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator","volume":"57","author":"Tran","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2023.11.018_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A\u00a0placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.11.018_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/cer-2019-0169","article-title":"Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis","volume":"9","author":"Swallow","year":"2020","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.cgh.2023.11.018_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221133163","article-title":"S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review","volume":"15","author":"Constantinescu","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.cgh.2023.11.018_bib12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cgh.2023.11.018_bib13","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cgh.2023.11.018_bib14","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1177\/13524585221102584","article-title":"Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: up to 5 years of follow-up in the DAYBREAK open-label extension trial","volume":"28","author":"Cree","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.cgh.2023.11.018_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102844","article-title":"Ozanimod in relapsing multiple sclerosis: pooled safety results from the clinical development program","volume":"51","author":"Selmaj","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.cgh.2023.11.018_bib16","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.11.018_bib17","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cgh.2023.11.018_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cgh.2023.11.018_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jcph.244","article-title":"Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration","volume":"54","author":"Brossard","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2023.11.018_bib20","series-title":"Velsipity [package insert]","year":"2023"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2023.11.018_bib21","doi-asserted-by":"crossref","first-page":"i619","DOI":"10.1093\/ecco-jcc\/jjac190.0620","article-title":"Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials [abstract P49]","volume":"17","author":"Vermeire","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.11.018_bib22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.11.018_bib23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.11.018_bib24","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl","key":"10.1016\/j.cgh.2023.11.018_bib25","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.14309\/01.ajg.0000798752.72296.f3","article-title":"Ozanimod first-dose cardiac effects in patients with moderately to severely active ulcerative colitis and relapsing multiple sclerosis [abstr P038]","volume":"116","author":"Long","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.11.018_bib26","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/archinte.164.13.1389","article-title":"Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials","volume":"164","author":"Ko","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cgh.2023.11.018_bib27","series-title":"Calcium Channel Blockers. StatPearls","author":"McKeever","year":"2022"},{"key":"10.1016\/j.cgh.2023.11.018_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.cgh.2023.11.018_bib29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14656566.2022.2071605","article-title":"An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis","volume":"23","author":"Rowan","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cgh.2023.11.018_bib30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.11.018_bib31","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","volume":"17","author":"Solitano","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.11.018_bib32","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523009564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523009564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T20:12:05Z","timestamp":1731096725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523009564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1542356523009564"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.11.018","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}